Koichiro Tatsumi Selected Research

Hemoptysis

1/2020	Successful transcatheter arterial embolization in an asymptomatic patient with primary racemose hemangioma of the bronchial artery.
7/2017	The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study.
1/2017	Pulmonary Endometriosis which Probably Occurred through Hematogenous Metastasis after Artificial Abortion.
1/2015	Alveolar hemorrhage associated with pemetrexed administration.
9/2007	[A case of intractable hemoptysis originating from the branches of the right subclavian artery, successfully treated with arterial coil embolization].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Koichiro Tatsumi Research Topics

Disease

52	Pulmonary Hypertension 04/2022 - 05/2002
40	Neoplasms (Cancer) 01/2022 - 05/2002
24	Pulmonary Arterial Hypertension 05/2022 - 06/2004
23	Chronic Obstructive Pulmonary Disease (COPD) 01/2021 - 08/2002
21	Hypoxia (Hypoxemia) 05/2022 - 05/2002
14	Lung Injury 01/2022 - 01/2007
12	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021 - 01/2002
12	Obstructive Sleep Apnea 01/2020 - 03/2003
11	Fibrosis (Cirrhosis) 06/2021 - 10/2011
11	Lung Neoplasms (Lung Cancer) 01/2021 - 06/2007
11	Idiopathic Pulmonary Fibrosis 01/2020 - 06/2005
10	Inflammation (Inflammations) 12/2021 - 01/2005
10	Mesothelioma 05/2018 - 05/2012
10	Carcinoma (Carcinomatosis) 03/2018 - 03/2002
9	Vascular Remodeling 12/2021 - 09/2006
9	Pulmonary Fibrosis (Fibrosing Alveolitis) 06/2021 - 11/2014
9	Infections 01/2020 - 01/2004
9	Dyspnea (Shortness of Breath) 04/2019 - 01/2009
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2017 - 12/2002
6	Pneumonia (Pneumonitis) 01/2022 - 10/2011
6	Emphysema 01/2021 - 08/2004
5	Lung Diseases (Lung Disease) 01/2020 - 08/2004
5	Hemoptysis 01/2020 - 09/2007
5	Disease Progression 01/2020 - 01/2013
5	Apnea 01/2020 - 03/2005
5	Respiratory Insufficiency (Respiratory Failure) 01/2019 - 09/2016
5	Malignant Mesothelioma 01/2017 - 01/2008
4	Body Weight (Weight, Body) 01/2022 - 05/2002
4	Familial Primary Pulmonary Hypertension 01/2021 - 01/2014
4	Pulmonary Alveolar Proteinosis 01/2020 - 06/2010
4	Hemorrhage 01/2019 - 01/2015
4	Adenocarcinoma 01/2015 - 12/2011
4	Neoplasm Metastasis (Metastasis) 01/2013 - 05/2002
3	Sarcoidosis (Schaumann Disease) 01/2022 - 01/2013
3	Atherosclerosis 01/2021 - 03/2017
3	Pulmonary Edema 10/2020 - 03/2019
3	Adenocarcinoma of Lung 07/2017 - 12/2013
3	Asthma (Bronchial Asthma) 01/2017 - 11/2010
3	Hypercapnia 11/2016 - 02/2005
3	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 05/2016 - 02/2004
3	Pathologic Constriction (Stenosis) 01/2016 - 02/2004

Drug/Important Bio-Agent (IBA)

16	Pharmaceutical PreparationsIBA 01/2022 - 07/2012
12	Cisplatin (Platino)FDA LinkGeneric 03/2018 - 12/2005
11	Oxygen (Dioxygen)IBA 01/2022 - 03/2005
10	Bleomycin (Blenoxane)FDA LinkGeneric 06/2021 - 01/2008
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2011
8	Biomarkers (Surrogate Marker)IBA 01/2020 - 04/2008
8	CytokinesIBA 11/2018 - 06/2003
7	Semaxinib (SU5416)IBA 05/2022 - 11/2007
6	nintedanibIBA 01/2020 - 07/2017
6	GoldIBA 01/2017 - 12/2003
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 05/2022 - 11/2007
5	LipopolysaccharidesIBA 01/2022 - 08/2014
5	Anti-Bacterial Agents (Antibiotics)IBA 07/2020 - 08/2004
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020 - 04/2008
5	AutoantibodiesIBA 01/2019 - 04/2008
5	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2018 - 11/2010
5	Fas Ligand Protein (Fas Ligand)IBA 01/2005 - 03/2002
4	InterleukinsIBA 01/2022 - 01/2012
4	Phosphodiesterase 5 InhibitorsIBA 01/2021 - 01/2012
4	Epoprostenol (Prostacyclin)FDA LinkGeneric 10/2020 - 06/2004
4	p38 Mitogen-Activated Protein KinasesIBA 09/2020 - 12/2006
4	Tyrosine Kinase InhibitorsIBA 01/2020 - 12/2011
4	Cytotoxins (Cytolysins)IBA 01/2019 - 06/2004
4	AnticoagulantsIBA 01/2019 - 06/2011
4	SurvivinIBA 09/2017 - 06/2015
4	MidkineIBA 09/2017 - 06/2015
4	Diphosphonates (Bisphosphonates)IBA 12/2016 - 05/2012
4	Zoledronic Acid (Zometa)FDA Link 12/2016 - 05/2012
4	CaspasesIBA 06/2015 - 05/2012
4	SmokeIBA 08/2014 - 04/2007
3	SteroidsIBA 01/2022 - 01/2015
3	RNA (Ribonucleic Acid)IBA 01/2022 - 09/2020
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2008
3	Vasodilator Agents (Vasodilators)IBA 12/2021 - 03/2019
3	EnzymesIBA 12/2021 - 06/2004
3	AntibodiesIBA 01/2021 - 01/2020
3	CollagenIBA 09/2020 - 10/2011
3	riociguatIBA 01/2020 - 09/2013
3	pirfenidoneIBA 01/2019 - 07/2017
3	Metformin (Glucophage)FDA LinkGeneric 01/2017 - 07/2012
3	Endothelin Receptor AntagonistsIBA 12/2016 - 01/2012
3	lipoarabinomannan (LAM)IBA 05/2016 - 02/2004
3	MonocrotalineIBA 01/2016 - 12/2010
3	Pemetrexed (MTA)FDA Link 01/2015 - 07/2012
3	Fibrinogen (Factor I)FDA Link 01/2014 - 10/2010
3	Gefitinib (Iressa)FDA Link 12/2013 - 12/2011
3	ErbB Receptors (EGF Receptor)IBA 12/2013 - 12/2011
3	VaccinesIBA 10/2012 - 09/2002
3	CD40 Ligand (CD40L)IBA 07/2012 - 06/2003
3	Irinotecan (Camptosar)FDA LinkGeneric 10/2010 - 06/2004
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2007 - 07/2003
2	Interleukin-8 (Interleukin 8)IBA 01/2022 - 01/2008

Therapy/Procedure

38	Therapeutics 01/2022 - 03/2003
17	Endarterectomy (Thromboendarterectomy) 04/2022 - 06/2008
15	Drug Therapy (Chemotherapy) 09/2019 - 01/2007
6	Lung Transplantation 07/2021 - 02/2004
5	Radiotherapy 09/2017 - 12/2002
4	Continuous Positive Airway Pressure 01/2020 - 03/2003
4	Aftercare (After-Treatment) 05/2019 - 12/2007